The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats

D. Ratnam, G. Chandraiah, A. K. Meena, P. Ramarao, M.N.V. Ravi Kumar

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Obesity is the major cause of type 2 diabetes with hyperlipidemia as one of its complications and antioxidants were found to be beneficial in such disease conditions. The present investigation is geared towards reduction of the dose required/improve the bioavailability of the combination of antioxidants, ellagic acid and coenzyme Q10 by co-encapsulating them into nanoparticles and study the possible synergism in ameliorating hyperlipidemia in high fat diet fed rats. The co-encapsulated particles at 10% (w/w of polymer) loading of ellagic acid and coenzyme Q10 have particle size of 260 nm. Male Sprague-Dawley (SD) rats on feeding high fat diet for over 4 weeks developed hyperlipidemia. The hyperlipidemic rats on 2 weeks post treatment with antioxidant combination administered as oral suspension or nanoparticles found to ameliorate the hyperlipidemic conditions and nanoparticles were found to be equally/more effective at 3 times lower dose in sustaining cholesterol lowering effect for extended periods, lowering glucose and triglycerides and in improving endothelial functioning, indicating the ability of the nanoparticles in improving efficacy of the duo. The results promise the potential of nanoparticles in improving the efficacy of ellagic acid and coenzyme Q10 in treating high fat diet induced hyperlipidemia in rats.
Original languageEnglish
Pages (from-to)6741-6746
Number of pages5
JournalJournal of Nanoscience and Nanotechnology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

coenzyme Q10
Ellagic acid
Ellagic Acid
coenzymes
Coenzymes
diets
fats
antioxidants
Nutrition
Oils and fats
Antioxidants
rats
Rats
Fats
Nanoparticles
nanoparticles
acids
obesity
bioavailability
dosage

Keywords

  • antioxidants
  • hyperlipidemia
  • nanoparticles
  • bioavailability
  • plga nanoparticles
  • diabetes-mellitus
  • reactive protein
  • statin therapy
  • oral delivery
  • in-vitro
  • cholesterol
  • nephrotoxicity
  • atorvastatin
  • cyclosporine

Cite this

Ratnam, D. ; Chandraiah, G. ; Meena, A. K. ; Ramarao, P. ; Kumar, M.N.V. Ravi. / The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats. In: Journal of Nanoscience and Nanotechnology. 2009 ; Vol. 9, No. 11. pp. 6741-6746.
@article{4de841e386994b519ca60d4657cdb865,
title = "The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats",
abstract = "Obesity is the major cause of type 2 diabetes with hyperlipidemia as one of its complications and antioxidants were found to be beneficial in such disease conditions. The present investigation is geared towards reduction of the dose required/improve the bioavailability of the combination of antioxidants, ellagic acid and coenzyme Q10 by co-encapsulating them into nanoparticles and study the possible synergism in ameliorating hyperlipidemia in high fat diet fed rats. The co-encapsulated particles at 10{\%} (w/w of polymer) loading of ellagic acid and coenzyme Q10 have particle size of 260 nm. Male Sprague-Dawley (SD) rats on feeding high fat diet for over 4 weeks developed hyperlipidemia. The hyperlipidemic rats on 2 weeks post treatment with antioxidant combination administered as oral suspension or nanoparticles found to ameliorate the hyperlipidemic conditions and nanoparticles were found to be equally/more effective at 3 times lower dose in sustaining cholesterol lowering effect for extended periods, lowering glucose and triglycerides and in improving endothelial functioning, indicating the ability of the nanoparticles in improving efficacy of the duo. The results promise the potential of nanoparticles in improving the efficacy of ellagic acid and coenzyme Q10 in treating high fat diet induced hyperlipidemia in rats.",
keywords = "antioxidants, hyperlipidemia, nanoparticles, bioavailability, plga nanoparticles, diabetes-mellitus, reactive protein, statin therapy, oral delivery, in-vitro, cholesterol, nephrotoxicity, atorvastatin, cyclosporine",
author = "D. Ratnam and G. Chandraiah and Meena, {A. K.} and P. Ramarao and Kumar, {M.N.V. Ravi}",
year = "2009",
month = "11",
doi = "10.1166/jnn.2009.1461",
language = "English",
volume = "9",
pages = "6741--6746",
journal = "Journal of Nanoscience and Nanotechnology",
issn = "1533-4880",
number = "11",

}

The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats. / Ratnam, D.; Chandraiah, G.; Meena, A. K.; Ramarao, P.; Kumar, M.N.V. Ravi.

In: Journal of Nanoscience and Nanotechnology, Vol. 9, No. 11, 11.2009, p. 6741-6746.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats

AU - Ratnam, D.

AU - Chandraiah, G.

AU - Meena, A. K.

AU - Ramarao, P.

AU - Kumar, M.N.V. Ravi

PY - 2009/11

Y1 - 2009/11

N2 - Obesity is the major cause of type 2 diabetes with hyperlipidemia as one of its complications and antioxidants were found to be beneficial in such disease conditions. The present investigation is geared towards reduction of the dose required/improve the bioavailability of the combination of antioxidants, ellagic acid and coenzyme Q10 by co-encapsulating them into nanoparticles and study the possible synergism in ameliorating hyperlipidemia in high fat diet fed rats. The co-encapsulated particles at 10% (w/w of polymer) loading of ellagic acid and coenzyme Q10 have particle size of 260 nm. Male Sprague-Dawley (SD) rats on feeding high fat diet for over 4 weeks developed hyperlipidemia. The hyperlipidemic rats on 2 weeks post treatment with antioxidant combination administered as oral suspension or nanoparticles found to ameliorate the hyperlipidemic conditions and nanoparticles were found to be equally/more effective at 3 times lower dose in sustaining cholesterol lowering effect for extended periods, lowering glucose and triglycerides and in improving endothelial functioning, indicating the ability of the nanoparticles in improving efficacy of the duo. The results promise the potential of nanoparticles in improving the efficacy of ellagic acid and coenzyme Q10 in treating high fat diet induced hyperlipidemia in rats.

AB - Obesity is the major cause of type 2 diabetes with hyperlipidemia as one of its complications and antioxidants were found to be beneficial in such disease conditions. The present investigation is geared towards reduction of the dose required/improve the bioavailability of the combination of antioxidants, ellagic acid and coenzyme Q10 by co-encapsulating them into nanoparticles and study the possible synergism in ameliorating hyperlipidemia in high fat diet fed rats. The co-encapsulated particles at 10% (w/w of polymer) loading of ellagic acid and coenzyme Q10 have particle size of 260 nm. Male Sprague-Dawley (SD) rats on feeding high fat diet for over 4 weeks developed hyperlipidemia. The hyperlipidemic rats on 2 weeks post treatment with antioxidant combination administered as oral suspension or nanoparticles found to ameliorate the hyperlipidemic conditions and nanoparticles were found to be equally/more effective at 3 times lower dose in sustaining cholesterol lowering effect for extended periods, lowering glucose and triglycerides and in improving endothelial functioning, indicating the ability of the nanoparticles in improving efficacy of the duo. The results promise the potential of nanoparticles in improving the efficacy of ellagic acid and coenzyme Q10 in treating high fat diet induced hyperlipidemia in rats.

KW - antioxidants

KW - hyperlipidemia

KW - nanoparticles

KW - bioavailability

KW - plga nanoparticles

KW - diabetes-mellitus

KW - reactive protein

KW - statin therapy

KW - oral delivery

KW - in-vitro

KW - cholesterol

KW - nephrotoxicity

KW - atorvastatin

KW - cyclosporine

U2 - 10.1166/jnn.2009.1461

DO - 10.1166/jnn.2009.1461

M3 - Article

VL - 9

SP - 6741

EP - 6746

JO - Journal of Nanoscience and Nanotechnology

JF - Journal of Nanoscience and Nanotechnology

SN - 1533-4880

IS - 11

ER -